Impressively partnered Rani Therapeutics Inc.'s latest round of "more than $50 million" brings to greater than $70 million the amount of cash raised thus far by the firm, which "could be in the clinic in the second half of next year with a molecule that we might develop on our own," CEO Mir Imran told BioWorld Today.